These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8147300)

  • 1. Ventricular fibrillation induced by low-energy shocks from programmable implantable cardioverter-defibrillators in patients with coronary artery disease.
    Lauer MR; Young C; Liem LB; Ottoboni L; Peterson J; Goold P; Sung RJ
    Am J Cardiol; 1994 Mar; 73(8):559-63. PubMed ID: 8147300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low energy cardioversion with the implantable cardioversion defibrillator devices for treatment of ventricular tachycardia and ventricular fibrillation].
    Siebels J; Schneider MA; Kuck KH
    Z Kardiol; 1993 Nov; 82(11):683-91. PubMed ID: 8291289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator.
    Neglia JJ; Krol RB; Giorgberidze I; Mathew P; Lewis C; Munsif AN; Saksena S
    J Interv Card Electrophysiol; 1997 Feb; 1(1):49-56. PubMed ID: 9869951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%.
    Grimm W; Hoffmann J Jü; Müller HH; Maisch B
    J Am Coll Cardiol; 2002 Mar; 39(5):780-7. PubMed ID: 11869841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of shock timing on efficacy and safety of internal cardioversion for ventricular tachycardia.
    Li HG; Yee R; Mehra R; DeGroot P; Klein GJ; Zardini M; Thakur RK; Morillo CA
    J Am Coll Cardiol; 1994 Sep; 24(3):703-8. PubMed ID: 8077542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
    Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
    J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
    Böcker D; Haverkamp W; Block M; Borggrefe M; Hammel D; Breithardt G
    Circulation; 1996 Jul; 94(2):151-7. PubMed ID: 8674173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Termination of ventricular tachycardia by far-field stimulation in humans: a feasibility study.
    Lawo T; Schrader J; Buddensiek M; Schweika O; Mügge A; Bösche LI
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):1540-7. PubMed ID: 21039638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular arrhythmia detection for contemporary Biotronik and Abbott implantable cardioverter defibrillators with markedly prolonged detection in Biotronik devices.
    Oesterle A; Dhruva SS; Pellegrini CN; Liem B; Raitt MH
    J Interv Card Electrophysiol; 2023 Oct; 66(7):1679-1691. PubMed ID: 36737506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators.
    Lampert R; McPherson CA; Clancy JF; Caulin-Glaser TL; Rosenfeld LE; Batsford WP
    J Am Coll Cardiol; 2004 Jun; 43(12):2293-9. PubMed ID: 15193696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS; Bockstall K; Weinstock J; Alsheikh-Ali AA; Semsarian C; Estes NAM; Spirito P; Haas TS; Rowin EJ; Maron MS; Maron BJ
    J Cardiovasc Electrophysiol; 2017 May; 28(5):531-537. PubMed ID: 28240435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular tachycardia initiated by high energy cardioversion in a patient with an implantable cardioverter defibrillator.
    Chinushi M; Aizawa Y; Higuchi K
    Heart; 1997 Apr; 77(4):373-4. PubMed ID: 9155621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
    Raitt MH; Klein RC; Wyse DG; Wilkoff BL; Beckman K; Epstein AE; Coromilas J; Friedman PL; Martins J; Ledingham RB; Greene HL;
    Am J Cardiol; 2003 Apr; 91(7):812-6. PubMed ID: 12667566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators.
    Enriquez A; Biagi J; Redfearn D; Boles U; Kamel D; Ali FS; Hopman WM; Michael KA; Simpson C; Abdollah H; Campbell D; Baranchuk A
    JACC Clin Electrophysiol; 2017 Jan; 3(1):50-56. PubMed ID: 29759695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.